This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
SSc is a heterogeneous, often devastating CTD that affects the skin and other organs3,4
SSc typically occurs between the ages of 30 to 605
SSc affects 3x more women than men3
ILD is the leading cause of mortality in the SSc population6
For most patients with SSc,
pulmonary involvement
often evident within three years
of diagnosis7
Pulmonary fibrosis
can affect
of patients with
diffuse cutaneous SSc8
Pulmonary fibrosis
can affect
of those with
limited cutaneous SSc8
Anna-Maria Hoffman-Vold, Postdoctoral Researcher at Oslo University Hospital,
talks about how she monitors patients with SSc-ILD
Pulmonary fibrosis is unpredictable—deterioration in pulmonary function tests (PFTs) should trigger urgency for further investigation9,10
Non-CTD ILD patient profiles
Download profiles of patients with a range of ILDs, to view their background, diagnostic history and pulmonary function evaluation
Ben
Ben has IPF
Caroline
Caroline has IPF
Robert
Robert has chronic hypersensitivity pneumonitis (cHP)
Make regular pulmonary function tests (PFTs) routine in patients susceptible to CTD-ILD2
CTD-ILD patient profiles
Download profiles of patients with a range of CTD-ILDs, to view their background, diagnostic history and pulmonary function evaluation
Julie
Julie has RA-ILD
Stephanie
Stephanie has limited cutaneous SSc-lLD
Early supportive care can help maintain physical and emotional wellbeing in patients with ILD12
Your vigilance matters when it comes to progressive fibrosing ILD.
1.
Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27:180076.
2.
Koo S-M, Uh S-T. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. Korean J Intern Med. 2017;32(4):600-610.
3.
Muangchan C, Baron M, Pope J; Canadian Scleroderma Research Group. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. J Rheumatol. 2013;40(9):1545-1556.
4.
Van den Hoogen F, Khanna D, Frasen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737-2747.
5.
Olsen AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressivefibrosing phenotype. Eur Respir Rev. 2018;27:180077.
6.
Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-1815.
7.
Solomon J, Olsen AL, Fisch3er A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6-19.
8.
Walker UA, Tyndall A, Czirják L, Brown KK. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66(6):754-763.
9.
Raghu G, Collard HR, Egan JJ, et al; on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
10.
Martinez FJ, Flaherty K. Pulmonary function testing in idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):315-321.
11.
Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of ... in patients with progressive fibrosing interstitial lung disease. BMJ Open Resp Res. 2017;4(1):e000212.
12.
Theodore AC, Tseng C-H, Li N, Elashoff RM, Tashkin DP. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest. 2012;142(3):614-621.
13.
Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91(suppl 2):S3-S10.
14.
Kreuter M, Swigris J, Pittrow D, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information on pulmonary fibrosis.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the US and UK and have read and understood this disclaimer.